Reimagining RNA medicine

Aug 10, 2026

Wave Life Sciences Announces Completion of Redomiciliation to Delaware

Aug 05, 2026

Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware

Aug 04, 2026

Wave Life Sciences to Present at Upcoming Investor Conferences

Jul 30, 2026

Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 23, 2026

Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026

Jul 07, 2026

Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation

Jun 24, 2026

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT™ Trial of WVE-007 (INHBE GalNAc-siRNA) for Obesity and Cardiometabolic Diseases

Jun 01, 2026

Wave Life Sciences to Present at Upcoming Investor Conferences

May 18, 2026

Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

May 13, 2026

Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference